BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 184 filers reported holding BRIDGEBIO PHARMA INC in Q3 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,460,650 | +31.8% | 245,000 | -14.0% | 0.05% | +31.4% |
| Q2 2023 | $4,902,000 | +12.7% | 285,000 | 0.0% | 0.04% | +16.7% |
| Q1 2023 | $4,349,303 | +493.1% | 285,000 | +196.1% | 0.03% | +500.0% |
| Q4 2022 | $733,345 | -23.0% | 96,244 | +0.5% | 0.01% | -28.6% |
| Q3 2022 | $952,000 | -73.9% | 95,775 | -76.2% | 0.01% | -76.7% |
| Q2 2022 | $3,649,000 | -10.5% | 401,912 | 0.0% | 0.03% | +7.1% |
| Q1 2022 | $4,079,000 | -39.2% | 401,912 | 0.0% | 0.03% | -34.9% |
| Q4 2021 | $6,704,000 | -68.6% | 401,912 | -11.7% | 0.04% | -70.3% |
| Q3 2021 | $21,338,000 | -23.1% | 455,285 | 0.0% | 0.14% | -23.7% |
| Q2 2021 | $27,754,000 | – | 455,285 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,835,722 | $103,449,000 | 44.18% |
| Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $995,211,000 | 12.26% |
| SC US (TTGP), LTD. | 2,544,738 | $68,632,000 | 4.69% |
| Cormorant Asset Management, LP | 2,780,885 | $75,000,000 | 4.31% |
| Perceptive Advisors | 6,706,268 | $180,868,000 | 4.15% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $717,968,000 | 3.22% |
| Hillhouse Capital Management | 2,035,790 | $54,905,000 | 1.75% |
| Alpine Group USVI, LLC | 20,000 | $539,000 | 1.70% |
| HHLR ADVISORS, LTD. | 2,352,900 | $63,458,000 | 1.42% |
| SCGE MANAGEMENT, L.P. | 588,235 | $15,865,000 | 0.79% |